Holen Sie sich die Stockscreener-App
24.94
0.95%
0.25
Schlusskurs vom Vortag:
$24.69
Offen:
$24.69
24-Stunden-Volumen:
276.53K
Relative Volume:
0.23
Marktkapitalisierung:
$3.04B
Einnahmen:
$588.99M
Nettoeinkommen (Verlust:
$214.33M
KGV:
14.81
EPS:
1.6844
Netto-Cashflow:
$208.61M
1W Leistung:
+4.81%
1M Leistung:
+2.82%
6M Leistung:
+20.23%
1J Leistung:
+8.04%
1-Tages-Spanne:
$24.54
$24.99
1-Wochen-Bereich:
$24.00
$25.14
52-Wochen-Spanne:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
24.93 | 3.02B | 588.99M | 214.33M | 208.61M | 1.6844 |
VRTX
Vertex Pharmaceuticals Inc
|
435.80 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
759.09 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.99 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.48 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.87 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals, Inc. (CPRX) stock price, news, quote and history - Yahoo Finance UK
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is It Too Late To Consider Catalyst Pharmaceuticals (CPRX) After Strong Multi Year Rerating? - sahmcapital.com
Catalyst Pharmaceuticals, Inc. (CPRX) latest stock news and headlines - Yahoo Finance Australia
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - TradingView
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - TradingView
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Catalyst Pharmaceuticals (CPRX) Still Attractively Priced After Recent Share Price Stability? - Yahoo Finance
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView
JPMorgan Chase & Co. Sells 54,915 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
New Strong Buy Stocks for March 31st - Yahoo Finance Singapore
Best Value Stocks to Buy for March 31st - Yahoo Finance Singapore
Aug Movers: Can Catalyst Pharmaceuticals Inc stock outperform in a bear marketEarnings Recap Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Trading And DCF Upside Signals - Yahoo Finance
Aug Mood: Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Mixed Long Term And Recent Shareholder Returns - Sahm
Insider Buy: Is Catalyst Pharmaceuticals Inc currently under institutional pressure2026 Fundamental Recap & Long-Term Investment Growth Plans - baoquankhu1.vn
Total Market Plus Equity Portfolio's Catalyst Pharmaceuticals Inc(CPRX) Holding History - gurufocus.com
Analysts see big upside in Catalyst Pharmaceuticals, Inc. (CPRX) - msn.com
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes - TradingView
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Strong Buy" by Brokerages - MarketBeat
Vanguard realigns reporting; Catalyst Pharmaceuticals (CPRX) shows 0% ownership - Stock Titan
Truist Financial Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to "Strong-Buy" - MarketBeat
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data - TradingView
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Forecasts - Yahoo Finance
Retail Trends: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Market WrapUp & Low Drawdown Momentum Ideas - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer - TradingView
Will Catalyst Pharmaceuticals Inc benefit from government policyWeekly Loss Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Is Catalyst Pharmaceuticals Inc a momentum stock2026 Growth vs Value & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum Cooldown - Sahm
Why Catalyst Pharmaceutical (CPRX) is a top value stock for the long term - MSN
CPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance Australia
Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026 - Stock Titan
Catalyst Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Listing on NASDAQ - Minichart
Catalyst Pharma Patent Trial Against Hetero USA Delayed - TipRanks
Catalyst Pharmaceuticals IncDistrict court delays bench trial to May 18, 2026SEC filing - marketscreener.com
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (NASDAQ: CPRX) FIRDAPSE patent trial pushed to May 2026 - Stock Titan
Catalyst Pharmaceuticals (CPRX) reports record Q4 and full year 2025 results - MSN
Catalyst Pharmaceuticals, Inc. (CPRX): A bull case theory - MSN
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Catalyst Pharmaceuticals Inc-Aktie (CPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Harper Molly | Director |
Dec 12 '25 |
Sale |
23.25 |
26,746 |
621,920 |
2,360 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):